MX2019011692A - Nuevo tratamiento de enfermedades mitocondriales. - Google Patents

Nuevo tratamiento de enfermedades mitocondriales.

Info

Publication number
MX2019011692A
MX2019011692A MX2019011692A MX2019011692A MX2019011692A MX 2019011692 A MX2019011692 A MX 2019011692A MX 2019011692 A MX2019011692 A MX 2019011692A MX 2019011692 A MX2019011692 A MX 2019011692A MX 2019011692 A MX2019011692 A MX 2019011692A
Authority
MX
Mexico
Prior art keywords
novel treatment
mitochondrial diseases
treatment
mitochondrial
diseases
Prior art date
Application number
MX2019011692A
Other languages
English (en)
Inventor
David BEYRATH Julien
Albertus Maria Smeitink Johannes
Original Assignee
Khondrion Ip B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Khondrion Ip B V filed Critical Khondrion Ip B V
Publication of MX2019011692A publication Critical patent/MX2019011692A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un tratamiento innovador para los trastornos mitocondriales y las enfermedades o afecciones asociadas con la disfunción mitocondrial. En particular, se han establecido dosis efectivas y seguras de compuestos adecuados para el tratamiento de trastornos mitocondriales, que se proporcionan para nuevos regímenes de tratamiento y poblaciones de pacientes.
MX2019011692A 2017-04-05 2017-09-05 Nuevo tratamiento de enfermedades mitocondriales. MX2019011692A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17165012 2017-04-05
PCT/EP2017/072172 WO2018184706A1 (en) 2017-04-05 2017-09-05 Novel treatment of mitochondrial diseases

Publications (1)

Publication Number Publication Date
MX2019011692A true MX2019011692A (es) 2020-02-10

Family

ID=58489616

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011692A MX2019011692A (es) 2017-04-05 2017-09-05 Nuevo tratamiento de enfermedades mitocondriales.

Country Status (8)

Country Link
US (2) US11285130B2 (es)
EP (2) EP3606522B1 (es)
KR (1) KR102660473B1 (es)
AU (1) AU2017408066B2 (es)
CA (1) CA3058033A1 (es)
ES (1) ES2959243T3 (es)
MX (1) MX2019011692A (es)
WO (1) WO2018184706A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3079483A1 (en) * 2017-11-22 2019-05-31 Khondrion Ip B.V. Compounds as mpges-1 inhibitors
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure
NL2031091B1 (en) * 2022-02-28 2023-09-07 Sulfateq Bv Chromanol compounds for treatment or prophylaxis of ageing and ageing-associated disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0204232D0 (en) 2002-02-22 2002-04-10 Isis Innovation Assay
EP3456707B1 (en) * 2007-11-06 2020-04-15 PTC Therapeutics, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
WO2012019032A1 (en) 2010-08-06 2012-02-09 Ampere Life Sciences, Inc. Treatment of mitochondrial diseases with vitamin k
JP6045494B2 (ja) 2010-08-06 2016-12-14 エジソン ファーマシューティカルズ， インコーポレイテッド ナフトキノンによるミトコンドリア病の処置
LT2872497T (lt) * 2012-07-12 2017-04-25 Khondrion Ip B.V. Chromanilo dariniai, skirti mitochondrinių ligų gydymui
US9388156B2 (en) * 2012-07-12 2016-07-12 Khondiron IP B.V. Chromanyl derivatives for treating mitochondrial disease
EP3359521A1 (en) * 2015-10-08 2018-08-15 Khondrion Ip B.V. Novel compounds for treating mitochondrial disease
KR20200090816A (ko) * 2017-11-22 2020-07-29 콘드리온 아이피 비.브이. 우울증 및 편두통 치료용 신규 화합물
CA3079483A1 (en) * 2017-11-22 2019-05-31 Khondrion Ip B.V. Compounds as mpges-1 inhibitors

Also Published As

Publication number Publication date
ES2959243T3 (es) 2024-02-22
US11285130B2 (en) 2022-03-29
EP4241842A3 (en) 2023-11-08
EP3606522A1 (en) 2020-02-12
EP3606522B1 (en) 2023-07-12
EP3606522C0 (en) 2023-07-12
AU2017408066A1 (en) 2019-11-21
KR20190133206A (ko) 2019-12-02
AU2017408066B2 (en) 2023-08-24
AU2017408066A2 (en) 2019-11-21
KR102660473B1 (ko) 2024-04-24
CA3058033A1 (en) 2018-10-11
EP4241842A2 (en) 2023-09-13
US20220265604A1 (en) 2022-08-25
WO2018184706A1 (en) 2018-10-11
US20210113520A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2021009830A (es) Metodos para el tratamiento de trastornos del movimiento involuntario anormal.
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
MY187540A (en) Compounds active towards bromodomains
GB2541571A (en) Pharmaceutical compositions
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
MX2017002489A (es) Agentes terapeuticos humanos.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2017014782A (es) Metodo para el tratamiento de enfermedad neurologica.
NZ745187A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
PH12020550255A1 (en) Treatment of smc mediated disease
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2019011692A (es) Nuevo tratamiento de enfermedades mitocondriales.
MX2018008643A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5] -decano.
TW201713323A (en) Therapeutic compositions and methods of use thereof
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
MX2017009608A (es) Compuestos anticancerigenos.